Matthew K. Szot, Chief Financial Officer at Cadrenal Therapeutics, Inc. (CVKD), sold 3,600 shares at $13.99 ($50K) on 2025-10-27, disclosed to the SEC on 2025-10-28.
Scheduled sale ($50k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.99 | 1,800 | $25K | 50.0% |
| 2 | $13.99 | 1,800 | $25K | 50.0% |
| Total | $13.99 avg | 3,600 | $50K | 100% |
| Filing → |
| SNES | SELL | 2025-11-17 | $3 | — | Filing → |
| CVKD | SELL | 2025-10-14 | $49K | — | Filing → |
| CVKD | SELL | 2025-10-07 | $1K | — | Filing → |